Arcutis Biotherapeutics, Inc.
US ˙ NasdaqGS ˙ US03969K1088

SecurityARQT / Arcutis Biotherapeutics, Inc.
InstitutionD. E. Shaw & Co., Inc.
ManagerDE Shaw
Latest Disclosed Ownership2,496,222 shares
Latest Disclosed Value $ 58,810,990
D. E. Shaw & Co., Inc. reports 6.96% decrease in ownership of ARQT / Arcutis Biotherapeutics, Inc.

On May 15, 2026 - D. E. Shaw & Co., Inc. filed a 13F-HR form disclosing ownership of 2,496,222 shares of Arcutis Biotherapeutics, Inc. (US:ARQT) valued at $58,810,990 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 2,683,087 shares of Arcutis Biotherapeutics, Inc.. This represents a change in shares of -6.96% during the quarter. The current value of the position is $53,294,340 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 2,496,222 -186,865 -6.96 58,811 -24.52 0.0354
2026-02-17 2025-12-31 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 2,683,087 564,374 26.64 77,917 95.10 0.0427
2025-11-14 2025-09-30 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 2,118,713 -44,288 -2.05 39,938 31.70 0.0225
2025-08-14 2025-06-30 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 2,163,001 173,493 8.72 30,325 -2.54 0.0215
2025-05-15 2025-03-31 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 1,989,508 -524,069 -20.85 31,116 -11.14 0.0277
2025-02-14 2024-12-31 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 2,513,577 768,553 44.04 35,014 115.76 0.0257
2024-11-14 2024-09-30 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 1,745,024 737,640 73.22 16,229 73.23 0.0139
2024-08-14 2024-06-30 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 1,007,384 790,518 364.52 9,369 335.92 0.0088
2024-05-15 2024-03-31 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 216,866 216,866 2,149 0.0018
2023-08-14 2023-06-30 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 0 -10,629 -100.00 0 -100.00
2023-05-15 2023-03-31 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 10,629 -26,547 -71.41 117 -78.91 0.0001
2023-02-14 2022-12-31 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 37,176 -37,200 -50.02 550 -61.29 0.0006
2022-11-14 2022-09-30 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 74,376 74,376 1,421 0.0017
2020-11-16 2020-09-30 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 0 -9,546 -100.00 0 -100.00
2020-08-14 2020-06-30 13F ARCUTIS BIOTHERAPEUTICS COM 03969K108 9,546 9,546 289 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.